Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mindy Magee

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Pharmacology Research & Perspectives|May 5, 2025
Population pharmacokinetics and exposure-response relationship for temsavir following fostemsavir administration in treatment-experienced HIV patientsRidhi Parasrampuria, Nilay Thakkar, Katy Moore, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 9, 2022
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjectsPeter Gorycki, Mindy Magee, Peter Ackerman, et al.
Clinical and Translational Science|February 7, 2020
Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response AnalysisChakradhar Lagishetty, Katy Moore, Peter Ackerman, et al.
Journal of Pharmaceutical Sciences|November 4, 2023
A Quantitative Clinical Pharmacology-Based Framework For Model-Informed Vaccine DevelopmentRajat Desikan, Massimiliano Germani, Piet H van der Graaf, et al.
HIV Research & Clinical Practice|March 14, 2022
Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participantsMary Beth Wire, Mindy Magee, Peter Ackerman, et al.
Infectious Diseases and Therapy|October 26, 2024
Correction to: Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b StudiesAmir S Youssef, Mohamed Ismail, Kelong Han, et al.
Infectious Diseases and Therapy|May 25, 2024
Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b StudiesAmir S Youssef, Mohamed Ismail, Kelong Han, et al.
Journal of Clinical Pharmacology|December 28, 2020
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of FostemsavirMindy Magee, Jill Slater, Frank Mannino, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 11, 2025
A Step-by-Step Workflow for Performing In Silico Clinical Trials With Nonlinear Mixed Effects ModelsJaviera Cortés-Ríos, Mindy Magee, Anna Sher, et al.
Pharmacology Research & Perspectives|July 11, 2024
No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approachesDung Nguyen, Xiusheng Miao, Kunal Taskar, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Pharmacology Research & Perspectives|May 5, 2025
Population pharmacokinetics and exposure-response relationship for temsavir following fostemsavir administration in treatment-experienced HIV patientsRidhi Parasrampuria, Nilay Thakkar, Katy Moore, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 9, 2022
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjectsPeter Gorycki, Mindy Magee, Peter Ackerman, et al.
Clinical and Translational Science|February 7, 2020
Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response AnalysisChakradhar Lagishetty, Katy Moore, Peter Ackerman, et al.
Journal of Pharmaceutical Sciences|November 4, 2023
A Quantitative Clinical Pharmacology-Based Framework For Model-Informed Vaccine DevelopmentRajat Desikan, Massimiliano Germani, Piet H van der Graaf, et al.
HIV Research & Clinical Practice|March 14, 2022
Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participantsMary Beth Wire, Mindy Magee, Peter Ackerman, et al.
Infectious Diseases and Therapy|October 26, 2024
Correction to: Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b StudiesAmir S Youssef, Mohamed Ismail, Kelong Han, et al.
Infectious Diseases and Therapy|May 25, 2024
Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b StudiesAmir S Youssef, Mohamed Ismail, Kelong Han, et al.
Journal of Clinical Pharmacology|December 28, 2020
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of FostemsavirMindy Magee, Jill Slater, Frank Mannino, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 11, 2025
A Step-by-Step Workflow for Performing In Silico Clinical Trials With Nonlinear Mixed Effects ModelsJaviera Cortés-Ríos, Mindy Magee, Anna Sher, et al.
Pharmacology Research & Perspectives|July 11, 2024
No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approachesDung Nguyen, Xiusheng Miao, Kunal Taskar, et al.
Pageof 3